retatrutide triple agonist glp-1 gip glucagon phase 2 obesity trial hormone receptor clinical results Retatrutide (Triple-Action Jab): III Mounjaro: Retatrutide and Diabetes -

In a randomized, placebo-controlled trial of semaglutide treatment, 62 % of adolescent participants in the semaglutide group achieved a loss of body weight of at least 10 %, with 37 % of subjects achieving weight reduction of at least 20 % [138,156]

This is particularly relevant for women on semaglutide, as the medication's effects on the gut microbiome are still being studied

95% CI, 0.860.92), cannabis (HR 0.88

(8) The base-case scenario assumed constant mortality rates

[DOI] [PMC free article] [PubMed] [Google Scholar] [118].Trujillo JM, Nuffer W, Ellis SL, GLP-1 receptor agonists: a review of head-to-head clinical studies, Ther Adv Endocrinol Metab, 6 (2015) 1928